A small oncology practice in Hawaii is struggling to find billing vendors familiar with Hawaii Medical Service Association (HMSA) and AlohaCare plan rules. They need a service provider experienced with Pacific region payer contracts and telehealth oncology claims.
In Hawaii, oncology billing comes down to three payer realities more than vendor size. HMSA carries most commercial volume, AlohaCare runs QUEST Integration Medicaid, and both apply heavy prior-auth and medical-necessity rules on chemo, biologics, and infusions.
Before you shortlist anyone, vet on these specifics:
- HMSA prior-auth and appeals depth on J-code drugs, plus clean administration coding (96401 to 96417) with accurate NDC reporting.
- AlohaCare QUEST timely-filing windows and encounter submission rules, which trip up mainland vendors.
- Telehealth oncology claims handling. Confirm correct POS (02 or 10) and modifier 95 usage, since payer policies here shifted post-PHE.
- Pacific time-zone support and awareness of Hawaii GET tax on billed services.
A few options worth a discovery call. Confirm each one’s actual HMSA and AlohaCare history directly, since most “national” vendors have thin Pacific experience:
| Vendor | Oncology depth | Telehealth claims | HMSA / AlohaCare experience | Compliance |
|---|---|---|---|---|
| Transcure | Dedicated oncology coders, infusion + J-code expertise | Yes, POS/modifier handling built in | Confirm in discovery; supports regional payer contracts | AAPC/AHIMA certified, signed BAA under 45 CFR 164.502(e) |
| Coronis Health | Strong oncology focus | Yes | Verify directly | HIPAA compliant |
| R1 RCM | Enterprise/hospital oncology | Yes | Verify directly | HIPAA compliant |
| AdvancedMD (+RCM) | Generalist, software-led | Yes | Verify directly | HIPAA compliant |
What separates a good fit from a bad one is denial recovery, not onboarding promises. Ask each vendor for a redacted HMSA denial-to-payment example on a chemo or biologic claim before you sign. If they can’t produce one, they don’t know your payers.
For a small practice, also weigh cost structure. Percentage-of-collections models scale with your volume better than flat PEPM when your case mix swings.
Disclosure: I work with Transcure, listed above for transparency. Happy to point you to neutral resources either way.
One angle worth flagging before the vendor question, because it shapes which vendor even makes sense.
For a small oncology practice, the bigger threat in Hawaii is not finding someone who knows HMSA prior auth. It is site-of-care steerage and white bagging. HMSA and the commercial plans have been pushing high-cost biologics and chemo toward contracted specialty pharmacy and away from buy-and-bill. If your practice is still acquiring and billing its own drugs, a vendor who does not actively track which regimens are getting forced to white bag will quietly let your margin erode one auth at a time. So when you evaluate anyone, ask specifically how they handle site-of-care denials and whether they flag white-bag mandates before the drug is ordered, not after it is sitting in your fridge.
Second thing that gets missed on small panels: wastage billing. JZ is mandatory now for single-dose vials with zero discard, and JW for the discarded amount. On expensive biologics, sloppy or absent wastage coding is real money left on the table every single infusion. Ask any vendor to walk you through how they reconcile vial size to dose to billed and wasted units. If they look at you blankly, that tells you what you need to know.
If the practice is hospital-affiliated or 340B in any way, add modifier tracking to that list, because mixing 340B and non-340B drug claims without clean JG or TB handling is an audit magnet.
On the local payer mechanics, the trap with HMSA oncology is that drug auths often route through a regimen or clinical pathway review, so on-pathway versus off-pathway matters as much as the auth itself. A vendor who has only done mainland commercial work tends to treat it as a generic prior auth and gets surprised. And on the AlohaCare QUEST side, the thing that breaks mainland billers is the encounter submission requirement, which is not the same workflow as a standard claim. Worth confirming any candidate has actually run QUEST encounters, not just QUEST claims.
Net for a practice your size: the drug economics question probably outranks the vendor logo. Sort that out first, then the shortlist gets a lot easier.